Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-10-19
EX-99.1
NeuroSense announced the filing of a U.S. patent application for PrimeC covering treatment of traumatic brain injury (TBI) and related CNS injuries. This represents a material strategic and operational development—expansion of the company's intellectual property portfolio and product pipeline beyond its primary ALS focus into a large, underserved market with no approved disease-modifying therapies. The filing strengthens IP position and creates foundation for future partnerships and non-dilutive funding, directly supporting long-term commercial value creation. While not a discrete M&A, financing, or clinical-trial event, it is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's growth prospects and asset value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-19
EX-99.1
The press release announces FDA approval of an IDE supplement expanding the REGAIN clinical trial from 10 to 20 patients and adding new study endpoints, along with acceptance of trial data for presentation at a major scientific conference. This is a material regulatory and clinical milestone for a clinical-stage medical device company, but does not fit the specific event categories (not an earnings release, executive change, M&A, impairment, or other named types). It represents a significant operational advancement in the company's clinical development program for its Alpha DaRT technology.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-10-19
Item 5.02
The disclosure centers on a new employment agreement with Jonathan Reich effective October 1, 2026, detailing compensatory arrangements including base salary ($390,000 with annual increases), performance bonus ($124,313 minimum), separation pay provisions, equity acceleration rights, and a 100,000-share equity award under the 2026 Equity Incentive Plan. While Reich's role change from CEO to President/COO occurred, the substantive focus of this Item 5.02 filing is the compensation structure and terms of his new employment agreement, making this primarily an exec_compensation disclosure rather than exec_departure or exec_appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-10-19
Item 5.02
The filing discloses the appointment of Anthony Evers as Fractional Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective October 19, 2026, following the termination of Luke McPherson on October 13, 2026. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO/PFO/PAO to fill the vacancy, making exec_appointment the most salient classification. The appointment is material as it addresses a critical financial officer role at the company.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-10-19
The filing discloses entry into two material definitive agreements under Item 1.01: promissory notes issued by Genvor to board members Dr. Jesse Jaynes ($20,408.16 principal) and Dr. Clayton Yates ($10,204.08 principal), each bearing 15% annual interest and maturing in six months. These represent creation of direct financial obligations and constitute debt issuance, though the related-party nature and board-member involvement raise governance considerations.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-10-19
EX-99.1
Mr. Stanford Ming Lin has been appointed as a member of the Board of Directors of TH International Limited. This is a clear executive appointment to the board, a governance event material to investors as it affects board composition and oversight. The biographical detail confirms his senior experience at major multinational corporations (RBI, Nestlé, Visa, Walmart) and prestigious educational credentials.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-19
Item 5.02
Tempest Therapeutics appointed John Frederick as a Class III director, effective October 13, 2026. The appointment was announced via press release on October 14, 2026, highlighting his extensive executive leadership experience in financial strategy, capital markets, and corporate governance. Frederick received an initial option award of 25,000 shares as part of his director compensation.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-10-19
EX-99.1
This is a press release dated October 19, 2026, providing an update on BW LPG's Product Services Q3 2026 segment performance, disclosing key financial metrics including gross trading result (US$164 million), realised trading result (US$146 million), and net profit after expenses and taxes (US$118 million). The release explicitly states "The trading result will form part of the BW LPG Q3 2026 results, which will be released on 24 November 2026," confirming this is a preliminary earnings disclosure for the third quarter. Material to investors assessing quarterly operational and financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-10-19
EX-99.1
This is a press release dated October 19, 2026, announcing Karooooo Ltd.'s second quarter and half-year 2027 unaudited financial results. The document presents detailed quarterly and half-year financial metrics including subscription revenue (ZAR1,415 million in Q2, up 20% Y/Y), operating profit (ZAR422 million, up 19% Y/Y), EPS (ZAR9.28, up 18% Y/Y), and subscriber growth (2.9 million, up 18% Y/Y). This is a discrete earnings announcement, not a periodic financial report filing itself, and would materially affect investor assessment of the company's financial performance and growth trajectory.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-10-19
EX-99.1
AIOS Tech Inc. announced entry into a transaction agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately US$100 million. The press release explicitly states the Company "has entered into a transaction agreement" and will "acquire all of the issued and outstanding shares of SmartCore," with issuance of 33,333,334 Class A common shares as consideration. This is a material acquisition that would significantly dilute existing shareholders (Sellers expected to hold ~80% post-closing) and expand AIOS's geographic and service capabilities in data center and network connectivity services.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-19
Item 8.01
Jaguar Uranium disclosed an independent mineral resource estimate (MRE) for its Laguna Salada Uranium-Vanadium Project in Argentina, announced via press release on October 13, 2026. The technical report and MRE, prepared in accordance with S-K 1300 standards, represent a material operational and strategic milestone for the exploration-stage uranium company, quantifying the mineral resource base and supporting future development planning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-19
EX-99.1
This press release discloses September 2026 operational and production metrics for Bitdeer's AI Cloud and Bitcoin mining businesses, including significant capacity expansions (67MW at A901, 60MW at A103), a major Malaysia facility contracting ($1.7B+ revenue over 5 years), a 16-year Norway lease ($4.7B contract value), land acquisition near Rockdale, and 200% Y/Y increase in Bitcoin production to 1,355 BTC. While these are operational updates rather than discrete M&A or financial events, the scale of capacity commitments, revenue backlog growth to ~$2.9B, and strategic infrastructure developments would materially affect a reasonable investor's assessment of the company's growth trajectory and operational capacity.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-10-19
The 6-K discloses the final voting results from an extraordinary general meeting of shareholders held on October 13, 2026. Four resolutions were submitted to a vote: (1) approval of a 1-for-200 share consolidation, (2) approval of a massive increase in authorized share capital from US$100,000 to US$5,000,000,000, (3) reduction of Class B voting power from 10 votes to 50 votes per share, and (4) adoption of amended memorandum and articles of association. All four resolutions passed with overwhelming majorities. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the structural changes (share consolidation, capital increase, voting power modification) are material to investors' assessment of the company's capital structure and governance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-10-19
Item 1.01
The filing discloses an assignment of an Equity Line of Credit (ELOC) from Euphoria Capital to Tunim Stone Capital, LLC, with company consent. While technically an assignment rather than a new issuance, the ELOC represents a direct financial obligation and credit facility that materially affects the company's capital structure and liquidity position. The assignment creates a new creditor relationship and modifies the terms of an existing financial obligation, which aligns most closely with debt_issuance in the taxonomy, though the assignment mechanism introduces some ambiguity about whether this is truly a new obligation or a transfer of an existing one.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-10-19
Item 2.03
The filing discloses unregistered sales of equity securities under Item 3.02, specifically "Waiver Pre-Funded Warrants and the Waiver Pre-Funded Warrant Shares" offered and sold in reliance on Section 4(a)(2) and Rule 506(b) exemptions. This is a classic private placement of dilutive securities. While Item 2.03 references a promissory note advance from the CSO, the primary material event disclosed is the unregistered equity issuance, which would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-10-19
Item 1.01
Rocky Mountain Chocolate Factory entered into a $2.0 million term loan with Alpine Bank on October 16, 2026, with a two-year maturity, variable interest rate (prime + 1.00%, floored at 6.00%), and security interests in substantially all company assets.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-19
Item 2.01
Rocky Mountain Chocolate Factory completed a sale-leaseback transaction on October 16, 2026, selling its Durango, Colorado manufacturing facility to American Heritage Legacies, LLC for $6.6 million and simultaneously entering into a commercial lease, with net proceeds used to repay $6.6 million in existing debt.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-10-19
Item 2.02
Rocky Mountain Chocolate Factory issued a press release on October 19, 2026, reporting financial results for the three months ended August 31, 2026 (fiscal Q2 2027), including revenue of $6.7 million and a net loss of $1.3 million or $(0.14) per share.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-19
Item 1.01
The Company entered into a material consultancy agreement with PEPE CEMERLANG MARKETING for brand strategy, identity development, and marketing services valued at USD 2,000,000 over an 18-month term.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-10-19
Item 3.02
The Company elected to satisfy milestone payments under the consultancy agreement through issuance of unregistered shares to the consultant, calculated by dividing the milestone payment by the last closing stock price, with a six-month holding period and Rule 144 restrictions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-19
The filing discloses an unregistered sale of 6,529,494 restricted shares of common stock to Mandragola Ltd. issued via cashless exercises of warrants between October 13-19, 2026. The shares were issued under Section 4(a)(2) exemption and represent a dilutive issuance that increased outstanding shares to 20,663,177. This is a material capital event typical of warrant exercises and dilutive equity issuances that would affect investor assessment of ownership and equity value.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-19
The filing discloses entry into a material definitive agreement (Item 1.01) whereby Treasure Global Inc's subsidiary or related entity (through Tadaa Capital Sdn. Bhd.) is acquiring 100% of the issued and paid-up share capital of Platinum Recognition Sdn. Bhd., a Malaysian hotel business operator, for RM2.4 million. The transaction includes an equity component—issuance of TGL common stock to an Escrow Agent as part of the payment scheme (Item 3.02)—making this a material acquisition with dilutive equity financing.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 89%
filed 2026-10-19
EX-99.1
Nexpu Ltd. completed an unregistered private placement of 40,000,000 units (each consisting of one Class A ordinary share and one warrant to purchase ordinary shares at $0.71 per share) at $0.70 per unit for aggregate gross proceeds of up to $28,000,000, relying on Section 4(a)(2) of the Securities Act and Regulation S exemptions to non-US persons. The issuance includes both the ordinary shares and warrants, representing a material dilutive capital-raising transaction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-10-19
EX-99.1
Chilwa announced the partial exercise of an over-allotment option by Maxim Group LLC, resulting in the issuance of 568,340 ordinary shares (via 56,834 ADSs) at US$5.59 per ADS, generating US$317,702 in gross proceeds. This is a dilutive equity issuance that increases the share count and raises capital, typical of post-IPO over-allotment exercises. The announcement explicitly states the number of shares issued and the proceeds, and notes that total US offering proceeds now stand at approximately US$3.82 million, making this a material capital-raising event for the recently listed company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-10-19
Item 1.01
OpenWorld entered into a definitive Agreement and Plan of Merger on October 16, 2026, to acquire Blocksight Holdings Co. via merger of OpenWorld's subsidiary into Blocksight, with Blocksight becoming a wholly owned subsidiary. The purchase price is 641,924 shares of common stock (approximately 4% of fully diluted capitalization), to be issued under Section 4(a)(2) and Rule 506 exemptions. Blocksight's AI agents will serve as the operating foundation for OpenWorld's tokenized financing programs.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-19
EX-99.1
This news release discloses Q2 Fiscal 2027 operational results (production and sales figures) and announces the timing of the full financial results release (November 5, 2026). While it includes production metrics and revenue ($72.1 million), it is not a formal earnings release of audited or unaudited financial statements—rather, it is an operational update preceding the actual financial results filing. The disclosure is material to investors as it reports significant production declines (41% silver, 34% gold, 42% silver equivalent, 41% lead, 51% zinc) due to safety system improvements, GC Mine suspension pending design approval, and construction progress on multiple projects. The operational nature and material impact on production justify classification as operational_other rather than earnings_release, since the full financial results are explicitly deferred to November 5, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-19
The exhibit discloses two operational events: (1) a new time-charter contract for M/V EM Corfu for 12–14 months at $62,500/day, expected to generate ~$17.8 million EBITDA and increase charter coverage; and (2) the sale of sister vessel M/V Evridiki G for ~$26 million with an expected gain on sale of ~$22.5 million (~$3.19 per share). While the sale involves a financial gain, the primary substance is operational—the deployment and disposition of fleet assets to maximize shareholder returns. This does not fit the specific categories of `ma_activity` (no acquisition or change of control), `financial_other` (not a capital structure or accounting event), or `dividend_distribution` (not a return of capital), but is clearly material to investors assessing the company's fleet strategy and near-term earnings.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-10-19
Item 2.02
This is a press release announcing the timing and logistics for Supernus Pharmaceuticals' third quarter 2026 financial results disclosure. The company explicitly states it "will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026" and will host a conference call with President and CEO Jack Khattar and CFO Tim Dec to discuss these results. This is a standard earnings announcement disclosure under Item 2.02, material to investors as it provides notice of upcoming quarterly financial performance disclosure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-10-19
Item 2.03
The filing discloses two separate debt drawdowns totaling $249.3 million ($177.5 million under an aircraft-secured credit facility and $71.8 million under a Boeing pre-delivery payment facility), both creating direct financial obligations. These are material debt issuances under Item 2.03, distinct from covenant breaches or existing debt amendments, with clear terms (fixed and floating rates, amortization schedules, and collateral assignments) and purposes (aircraft deliveries and Boeing pre-delivery payments).
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-10-19
Item 4.01
The filing discloses the appointment of Bansal & Co LLP as the Company's independent registered public accounting firm to review interim financial statements for the six months ended June 30, 2026. This represents a change in the registrant's certifying accountant under Item 4.01, which is a material governance event affecting the audit relationship and financial reporting oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-10-19
Item 5.07
This Item 5.07 disclosure reports the results of Taylor Devices' 2026 Annual Meeting of Shareholders held on October 16, 2026, with tabulated vote counts for three proposals: election of Timothy J. Sopko as a Class 2 director, ratification of Lumsden & McCormick, LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, and the disclosure is material as shareholder votes on director elections and auditor ratification directly affect governance and investor confidence.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-19
Item 5.02
CDW appointed Saranga (Sam) Balaji as a director effective October 15, 2026, increasing the board from nine to ten members. Mr. Balaji, a former Global CEO of Deloitte Consulting & Advisory with three decades of technology and business leadership experience, will serve on the Audit Committee.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-10-19
Item 5.07
iBio held its Annual Meeting of Stockholders and disclosed results of six proposals voted on by shareholders, including election of Class III directors (William Clark and Gary Sender), ratification of Grassi & Co. as auditor, say-on-pay approval, authorization to increase authorized Common Stock from 275 million to 500 million shares, approval of Amendment No. 1 to the 2023 Omnibus Incentive Plan, and meeting adjournment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-19
Item 2.02
AGNC Investment Corp. issued a press release on October 19, 2026 announcing its financial results for the quarter ended September 30, 2026, disclosing comprehensive loss of $(1.28) per share, tangible net book value of $7.13 per share, and other key financial metrics. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Condition), with the full press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-19
Item 7.01
Rekor filed a verified complaint in Delaware Court of Chancery against former director Viraj Mehta alleging breach of fiduciary duty in connection with a December 2025 financing. The complaint seeks compensatory damages, disgorgement, and restitution of director compensation. This is material litigation involving alleged misconduct by a director that directly affected a major financing transaction and the company's capital structure, warranting disclosure under Item 7.01 (Other Events) as a material legal matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-10-19
Item 5.07
Super League's stockholders approved all seven proposals at the October 16, 2026 Annual Meeting, including the transformative Metaplanet investment involving 2,100 Bitcoin (~$170M) and $2.5M cash, a company name change to Superplanet, charter amendments, and equity plan amendments. The approval fundamentally reshapes the company's capital structure and strategic direction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-10-19
Item 8.01
Clene announced submission of a New Drug Application (NDA) to the FDA for CNM-Au8 seeking accelerated approval for ALS treatment. This is a material regulatory milestone in the drug development process—a critical step toward potential commercialization of the company's lead candidate. While not fitting a specific named event type, this is clearly an operational/strategic business event that would affect a reasonable investor's assessment of the company's progress and prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-10-19
Item 8.01
The disclosure centers on H.B. Fuller's Board rejection of Ancora Holdings' second unsolicited proposal to acquire the Building Adhesive Solutions business for $1.2–$1.4 billion, coupled with the Company's announcement of a market check for select business segments with intent to use proceeds for deleveraging. While the immediate action is a rejection, the material event is the M&A activity—the unsolicited acquisition proposal and the Company's responsive strategic review process involving potential divestitures. This is a significant capital allocation and portfolio restructuring decision that would affect a reasonable investor's assessment of the registrant's strategy and financial position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-19
Item 8.01
BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, with substantive review and a meeting expected this quarter. This is a material regulatory milestone in the product development pathway that would affect investor assessment of the company's progress toward commercialization. While not a final approval, FDA acceptance of the pre-submission and commitment to substantive review represents a significant operational and regulatory advancement for a medical device company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-10-19
Item 5.02
The board designated Trent Green, the existing CEO, to serve as interim principal financial officer on October 14, 2026. While this is technically an appointment to an additional role rather than a new hire, the disclosure centers on the principal action of taking on a new officer position (interim CFO). The appointment is material because it signals a change in the company's financial leadership structure and may indicate an interim gap in permanent CFO coverage. No compensation changes were made, and no conflicts of interest exist.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-19
Item 5.02
Vaxart appointed Raquel C. Bono, M.D., a retired Vice Admiral and former Director of the Defense Health Agency, to its Board of Directors effective October 16, 2026. Dr. Bono brings extensive healthcare leadership and governance experience and will chair the Stockholder Engagement Committee while serving on the Nominating and Governance Committee and Clinical and Regulatory Affairs Committee.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-10-19
Item 5.02
The Board approved two compensatory arrangements on October 13, 2026: (1) the 1st Detect Corporation Transaction Incentive Bonus Plan, which establishes a bonus pool equal to 20% of transaction proceeds (minimum $20 million threshold) for designated key employees and the CEO, and (2) the First Amendment to the Astrotech Corporation Transaction Bonus Plan, modifying the definition of qualifying transactions. Both are material executive compensation arrangements tied to potential subsidiary sale transactions, disclosed under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-19
Item 5.02
Samantha L. Stoddard is being appointed as Vice President, Chief Financial Officer and Treasurer of Standex International, effective December 1, 2026. The filing centers on her appointment to this principal financial officer role, with detailed disclosure of her background, compensation arrangements (base salary of $575,000, target bonus of 75%, long-term incentive awards of 175% of base salary, signing bonus of $402,500, and sign-on equity awards totaling $1,406,250), and the transition from Ademir Sarcevic who will cease serving as CFO. This is a material executive appointment affecting the company's financial leadership.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-10-19
Item 1.01
Clene Inc. entered into a subaward amendment on October 15, 2026 for the fourth year of a $45.1 million NIH Grant, securing $7.2 million for the period September 1, 2026 to August 31, 2027 to support an Expanded Access Program for CNM-Au8® treatment of ALS. This is a material operational/strategic event involving continuation of a significant government research grant that supports the company's clinical program, but it does not fit the specific categories of M&A, debt issuance, equity issuance, or other defined event types—it is a material research funding agreement continuation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-19
Item 7.01
Transocean announced contract awards totaling $550 million in firm backlog for two ultra-deepwater drillships—the Deepwater Proteus ($325 million, 700-day campaign commencing Q1 2027) and the Deepwater Conqueror ($225 million, 450-day campaign commencing Q3 2027). This is a material operational and commercial milestone reflecting significant new revenue commitments for the company's core drilling services business, though it does not fit the specific categories of M&A, debt, equity issuance, or other defined event types.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-10-19
EX-99.1
VEON announces an agreement to acquire 100% of Rubicon Wireless (trading as "Perfectum"), a mobile network operator in Uzbekistan, for approximately USD 207 million inclusive of assumed debt. This is a material acquisition of a complementary competitor that expands spectrum holdings by ~50%, strengthens network assets, and represents a significant strategic investment in a core growth market. The transaction is expected to close by end of October 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-10-19
Item 8.01
Barrel Energy executed a letter of intent on October 14, 2026, to acquire a 51% controlling equity interest in Maine Bio-Fuel, Inc. for $20 million in cash and stock. Although the LOI is expressly non-binding except for limited provisions and closing is contingent on a separate exchange-listing transaction and other conditions, the disclosure of a proposed material acquisition with identified target, transaction structure, and consideration amount constitutes entry into M&A activity requiring 8-K disclosure under Item 1.01 or analogous provision. The materiality and specificity of the transaction (51% control stake, $20M consideration, identified business operations) would affect a reasonable investor's assessment of the registrant's strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-10-19
Item 5.02
BNB Standard Corporation appointed Alex Odagiu as Chief Executive Officer and principal executive officer, effective October 19, 2026, following a comprehensive CEO search by the Board's CEO Search Committee. Odagiu's compensation package includes a base salary of $525,000, a target bonus of 75%, equity grants of 2.5% of outstanding shares, and severance terms.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-10-19
Item 2.02
Chord Energy disclosed preliminary financial results for Q3 2026 via press release, including operational volumes, capital expenditures, cash position, debt levels, and adjusted free cash flow performance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-10-19
Item 5.02
Michael Lou was appointed President & Chief Executive Officer and elected to the Board effective October 19, 2026, succeeding Daniel Brown who resigned from both roles. Lou brings 25+ years of industry experience and 17 years with Chord and its predecessors.
View raw filing on EDGAR →